NFE2L2 and non-small cell lung carcinoma: Based on the evidence that NRF2 and GSH are determinants for cisplatin resistance in cell culture of lung cancer lines, we aimed to investigate if this is reflected in the prognostic of patients diagnosed with non-small cell lung cancer.